1. SUB-TYPE OF MDS: All
2. SEVERITY OF MDS: Low, or low to moderate
3. NAME OF DRUG: Deferasirox
4. Aims and benefits: This trial investigates how exactly chelation therapy can affect the health of patients with MDS and iron overload
5. Main basic inclusion criteria: MDS patients with Transfusional Iron Overload. Age over 18
6. Main basic exclusion criteria:
7. Trial sites/locations and name of physician in charge of trial:
8. More information: https://clinicaltrials.gov/ct2/show/NCT00940602

Please read information and always discuss trial information with your own physician.
Download information